Vertex Inc. (VERX)
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders
Thanks to its most recent acquisition, Vertex now has some promising products in the field of hormone disorders. These could eventually become meaningful growth drivers for the company.
Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It
Latigo Biotherapeutics is undervalued below IPO, with onzotrigine showing superior efficacy to Vertex's Journavx in acute pain. LTGO leverages Vertex's market groundwork, has pivotal-eligible Phase 2 data, and is funded into 2029, reducing near-term financing risk. Onzotrigine's Phase 3 bunionectomy trial is the key binary event; positive results could drive significant upside versus current market expectations.
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead
Vertex Pharmaceuticals NASDAQ: VRTX is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company's priorities, CEO and President Reshma Kewalramani said at Morgan Stanley's 24th Annual Healthcare Conference.
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis
Vertex Pharmaceuticals NASDAQ: VRTX highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance.
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference
Vertex Pharmaceuticals NASDAQ: VRTX outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis and rare endocrine disorders.
Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
3 Reasons Why Growth Investors Shouldn't Overlook Vertex (VERX)
Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story
Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech to a multi-franchise growth platform. 2Q26 revenue rose 12% to $3.33 billion, with strong CF performance and early scaling of Casgevy and Journvax supporting raised FY26 guidance to $13.1–$13.2 billion. VRTX is aggressively reinvesting in pipeline and commercial launches, leveraging a $13.6 billion cash position and diversifying with the Crinetics acquisition.
Vertex, Inc. (VERX) Q2 2026 Earnings Call Transcript
Vertex, Inc. (VERX) Q2 2026 Earnings Call Transcript
Vertex Q2 Earnings Call Highlights
Vertex NASDAQ: VERX reported second-quarter revenue at the high end of its guidance range and raised its full-year adjusted EBITDA outlook, as the tax technology company cited cost discipline, stable customer retention and growing demand for e-invoicing solutions.
Vertex Pharmaceuticals Q2 Earnings Call Highlights
Vertex Pharmaceuticals NASDAQ: VRTX reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX.
